{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:56:45Z","timestamp":1791212205646,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10801-z","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:36:18Z","timestamp":1791210978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials"],"prefix":"10.1007","author":[{"given":"Alana L.","family":"Sheehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Laynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Illenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-1995","authenticated-orcid":false,"given":"Sundar","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"10801_CR1","doi-asserted-by":"publisher","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. https:\/\/doi.org\/10.1038\/s41572-019-0097-9.","DOI":"10.1038\/s41572-019-0097-9"},{"issue":"24","key":"10801_CR2","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367\u20132375. https:\/\/doi.org\/10.1056\/NEJMra1615439.","journal-title":"N Engl J Med."},{"issue":"1","key":"10801_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u2013154. https:\/\/doi.org\/10.2337\/dc16-2042.","journal-title":"Diabetes Care."},{"key":"10801_CR4","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice C. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S59\u2013S85. https:\/\/doi.org\/10.2337\/dc25-S004.","DOI":"10.2337\/dc25-S004"},{"key":"10801_CR5","doi-asserted-by":"publisher","unstructured":"Kuo B, Li JH. Pharmacologic therapies for type 2 diabetes. NEJM Evid. 2025;4(9)https:\/\/doi.org\/10.1056\/EVIDra2400265.","DOI":"10.1056\/EVIDra2400265"},{"issue":"13","key":"10801_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","volume":"384","author":"RR Kalyani","year":"2021","unstructured":"Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. N Engl J Med. 2021;384(13):1248\u20131260. https:\/\/doi.org\/10.1056\/NEJMcp2000280.","journal-title":"N Engl J Med."},{"issue":"4","key":"10801_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa032782","volume":"352","author":"S Tesfaye","year":"2005","unstructured":"Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341\u201350. https:\/\/doi.org\/10.1056\/NEJMoa032782.","journal-title":"N Engl J Med."},{"key":"10801_CR8","doi-asserted-by":"publisher","unstructured":"Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;2012(6):CD007543. https:\/\/doi.org\/10.1002\/14651858.CD007543.pub2.","DOI":"10.1002\/14651858.CD007543.pub2"},{"key":"10801_CR9","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","DOI":"10.1136\/bmj.n160"},{"key":"10801_CR10","doi-asserted-by":"publisher","unstructured":"U. S. Preventive Services Task Force, Mangione CM, Barry MJ, et al. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(4):367\u2013374. https:\/\/doi.org\/10.1001\/jama.2022.10951.","DOI":"10.1001\/jama.2022.10951"},{"issue":"5","key":"10801_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"P Gaede","year":"2003","unstructured":"Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383\u201393. https:\/\/doi.org\/10.1056\/NEJMoa021778.","journal-title":"N Engl J Med."},{"issue":"18","key":"10801_CR12","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1161\/CIR.0000000000001383","volume":"152","author":"M Writing Committee","year":"2025","unstructured":"Writing Committee M, Otto CM, Abdullah AR, et al. 2025 ACC\/AHA Clinical Practice Guidelines Core Principles and Development Process: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(18):e359\u2013e370. https:\/\/doi.org\/10.1161\/CIR.0000000000001383.","journal-title":"Circulation."},{"issue":"10","key":"10801_CR13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1474-4422(22)00188-0","volume":"21","author":"MA Elafros","year":"2022","unstructured":"Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022;21(10):922\u2013936. https:\/\/doi.org\/10.1016\/S1474-4422(22)00188-0.","journal-title":"Lancet Neurol."},{"key":"10801_CR14","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee for D. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S132\u2013S149. https:\/\/doi.org\/10.2337\/dc26-S006.","DOI":"10.2337\/dc26-S006"},{"key":"10801_CR15","doi-asserted-by":"publisher","unstructured":"Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2014(2):CD009122. https:\/\/doi.org\/10.1002\/14651858.CD009122.pub2.","DOI":"10.1002\/14651858.CD009122.pub2"},{"issue":"7","key":"10801_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.2017.10169","volume":"318","author":"MY Johansen","year":"2017","unstructured":"Johansen MY, MacDonald CS, Hansen KB, et al. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(7):637\u2013646. https:\/\/doi.org\/10.1001\/jama.2017.10169.","journal-title":"JAMA."},{"key":"10801_CR17","unstructured":"Haddaway NR, Grainger MJ, Gray CT. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching (Version 0.0.3) [R package]. Zenodo. doi.org. 2021."},{"key":"10801_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"10801_CR19","doi-asserted-by":"crossref","unstructured":"Borenstein M. Introduction to meta-analysis. John Wiley & Sons; 2009:xxviii. p. 421.","DOI":"10.1002\/9780470743386"},{"issue":"4","key":"10801_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health."},{"key":"10801_CR21","unstructured":"Harrer M. Doing meta-analysis with R : a hands-on guide. First edition. ed. CRC Press\/Taylor & Francis Group; 2022:xxvi. pp. 474."},{"issue":"3","key":"10801_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw."},{"issue":"11","key":"10801_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med."},{"key":"10801_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S, Cochrane Collaboration. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence from: Cochrane handbook for systematic reviews of interventions. Cochrane book series. Wiley-Blackwell; 2008:xxi. p. 649.","DOI":"10.1002\/9780470712184"},{"key":"10801_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126\u2013135. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.10.014.","journal-title":"J Clin Epidemiol."},{"key":"10801_CR26","doi-asserted-by":"publisher","unstructured":"Ali MK, Singh K, Kondal D, et al. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial. PLoS Med. 2024;21(6):e1004335. https:\/\/doi.org\/10.1371\/journal.pmed.1004335.","DOI":"10.1371\/journal.pmed.1004335"},{"issue":"2","key":"10801_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431.","journal-title":"New England Journal of Medicine."},{"issue":"11","key":"10801_CR28","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/dom.12983","volume":"19","author":"SS Engel","year":"2017","unstructured":"Engel SS, Suryawanshi S, Stevens SR, et al. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab. 2017;19(11):1587\u20131593. https:\/\/doi.org\/10.1111\/dom.12983.","journal-title":"Diabetes, Obesity and Metabolism."},{"key":"10801_CR29","doi-asserted-by":"publisher","unstructured":"Hansen CS, Lundby-Christiansen L, Tarnow L, et al. Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. Cardiovasc Diabetol. 2020;19(1):150. https:\/\/doi.org\/10.1186\/s12933-020-01131-3.","DOI":"10.1186\/s12933-020-01131-3"},{"issue":"9739","key":"10801_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet. 2010;376(9739):419\u2013430. https:\/\/doi.org\/10.1016\/S0140-6736(10)60576-4.","journal-title":"The Lancet."},{"key":"10801_CR31","doi-asserted-by":"publisher","unstructured":"Khan S, Awan S, Channa H, Ahmed A, Wasay M. Structured Exercise Regimen in the Prevention of Peripheral Neuropathy in People with Type 2 Diabetes in a Low-Middle Income Country: An Open-Label, Randomized Controlled Trial. Clin Diabetol. 2023;12(6):336\u2013344. https:\/\/doi.org\/10.5603\/cd.95618.","DOI":"10.5603\/cd.95618"},{"issue":"10","key":"10801_CR32","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.2337\/dc13-0012","volume":"36","author":"R Pop-Busui","year":"2013","unstructured":"Pop-Busui R, Lu J, Brooks MM, et al. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013;36(10):3208\u20133215. https:\/\/doi.org\/10.2337\/dc13-0012.","journal-title":"Diabetes Care."},{"key":"10801_CR33","doi-asserted-by":"publisher","unstructured":"Rajamani K, Donoghoe M, Li L, et al. Abstract 18987: Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Circulation. 2010;122(suppl_21):A18987\u2013A18987. https:\/\/doi.org\/10.1161\/circ.122.suppl_21.A18987.","DOI":"10.1161\/circ.122.suppl_21.A18987"},{"issue":"5","key":"10801_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","volume":"58","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Lauria G, Iliev IP, et al. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension. 2011;58(5):776\u2013783. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.174474.","journal-title":"Hypertension."},{"issue":"1","key":"10801_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods."},{"issue":"5","key":"10801_CR36","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/ije\/dyn065","volume":"37","author":"NA Patsopoulos","year":"2008","unstructured":"Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148\u201357. https:\/\/doi.org\/10.1093\/ije\/dyn065.","journal-title":"Int J Epidemiol."},{"key":"10801_CR37","doi-asserted-by":"publisher","unstructured":"Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;(6)https:\/\/doi.org\/10.1002\/14651858.CD007543.pub2.","DOI":"10.1002\/14651858.CD007543.pub2"},{"key":"10801_CR38","doi-asserted-by":"publisher","unstructured":"Carvajal-Moreno L, Cohe\u00f1a-Jim\u00e9nez M, Garc\u00eda-Ventura I, Pab\u00f3n-Carrasco M, P\u00e9rez-Belloso AJ. Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review. J Clin Med. 2022;11(6)https:\/\/doi.org\/10.3390\/jcm11061723.","DOI":"10.3390\/jcm11061723"},{"key":"10801_CR39","doi-asserted-by":"publisher","unstructured":"Streckmann F, Balke M, Cavaletti G, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Med. 2022;52(5):1043\u20131065. https:\/\/doi.org\/10.1007\/s40279-021-01596-6.","DOI":"10.1007\/s40279-021-01596-6"},{"key":"10801_CR40","doi-asserted-by":"publisher","unstructured":"Fakkel TM, \u00c7akici N, Coert JH, Verhagen AP, Bramer WM, van Neck JW. Risk Factors for Developing Diabetic Peripheral Neuropathy: a Meta-analysis. SN Compr Clin Med. 2020;2(10):1853\u20131864. https:\/\/doi.org\/10.1007\/s42399-020-00480-0.","DOI":"10.1007\/s42399-020-00480-0"},{"issue":"2","key":"10801_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212574","volume":"14","author":"X Liu","year":"2019","unstructured":"Liu X, Xu Y, An M, Zeng Q. The risk factors for diabetic peripheral neuropathy: A meta-analysis. PLOS ONE. 2019;14(2):e0212574. https:\/\/doi.org\/10.1371\/journal.pone.0212574.","journal-title":"PLOS ONE."},{"key":"10801_CR42","doi-asserted-by":"publisher","first-page":"1564867","DOI":"10.3389\/fneur.2025.1564867","volume":"16","author":"P Zhou","year":"2025","unstructured":"Zhou P, Zhou JS, Li JJ, et al. Prevalence and risk factors for painful diabetic peripheral neuropathy: a systematic review and meta-analysis. Front Neurol. 2025;16:1564867. https:\/\/doi.org\/10.3389\/fneur.2025.1564867.","journal-title":"Front Neurol."},{"issue":"6","key":"10801_CR43","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/aje\/kwae332","volume":"194","author":"R Brignardello-Petersen","year":"2025","unstructured":"Brignardello-Petersen R, Guyatt GH. Assessing the certainty of the evidence in systematic reviews: importance, process, and use. Am J Epidemiol. 2025;194(6):1681\u20131686. https:\/\/doi.org\/10.1093\/aje\/kwae332.","journal-title":"Am J Epidemiol."},{"issue":"1","key":"10801_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14737175.2021.1847645","volume":"21","author":"S Demare","year":"2021","unstructured":"Demare S, Kothari A, Calcutt NA, Fernyhough P. Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system. Expert Rev Neurother. 2021;21(1):45\u201363. https:\/\/doi.org\/10.1080\/14737175.2021.1847645.","journal-title":"Expert Rev Neurother."},{"key":"10801_CR45","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2741\/2802","volume":"13","author":"R Kapadia","year":"2008","unstructured":"Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813\u201326. https:\/\/doi.org\/10.2741\/2802.","journal-title":"Front Biosci."},{"issue":"4","key":"10801_CR46","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2337\/diacare.28.4.956","volume":"28","author":"AJ Boulton","year":"2005","unstructured":"Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956\u201362. https:\/\/doi.org\/10.2337\/diacare.28.4.956.","journal-title":"Diabetes Care."},{"key":"10801_CR47","doi-asserted-by":"publisher","unstructured":"Vujkovic M, Keaton JM, Lynch JA, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52(7):680\u2013691. https:\/\/doi.org\/10.1038\/s41588-020-0637-y.","DOI":"10.1038\/s41588-020-0637-y"},{"issue":"5","key":"10801_CR48","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","volume":"54","author":"A Mahajan","year":"2022","unstructured":"Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560\u2013572. https:\/\/doi.org\/10.1038\/s41588-022-01058-3.","journal-title":"Nat Genet."},{"issue":"1","key":"10801_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41588-018-0303-9","volume":"51","author":"A Giri","year":"2019","unstructured":"Giri A, Hellwege JN, Keaton JM, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. Nat Genet. 2019;51(1):51\u201362. https:\/\/doi.org\/10.1038\/s41588-018-0303-9.","journal-title":"Nat Genet."},{"issue":"11","key":"10801_CR50","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41588-018-0222-9","volume":"50","author":"D Klarin","year":"2018","unstructured":"Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet. 2018;50(11):1514\u20131523. https:\/\/doi.org\/10.1038\/s41588-018-0222-9.","journal-title":"Nat Genet."},{"issue":"1","key":"10801_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70011","volume":"30","author":"U Adhikari","year":"2025","unstructured":"Adhikari U, Gad H, Chatterjee D, et al. Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study (DINE). J Peripher Nerv Syst. 2025;30(1):e70011. https:\/\/doi.org\/10.1111\/jns.70011.","journal-title":"J Peripher Nerv Syst."},{"issue":"3","key":"10801_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67(3):561\u2013566. https:\/\/doi.org\/10.1007\/s00125-023-06072-6.","journal-title":"Diabetologia."},{"key":"10801_CR53","doi-asserted-by":"crossref","unstructured":"Minor LB, Rees M. Discovering precision health : predict, prevent, and cure to advance health and well-being. Wiley-Blackwell; 2020:xii. pp. 266.","DOI":"10.1002\/9781119672715"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10801-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:36:21Z","timestamp":1791210981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10801-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":53,"alternative-id":["10801"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10801-z","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.Registered in PROSPERO before data extraction, CRD42025645451.","order":3,"name":"Ethics","label":"Clinical Trial\/Registration Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}